Hamzavi Ramin, Dolle Frédéric, Tavitian Bertrand, Dahl Otto, Nielsen Peter E
Department of Medical Biochemistry and Genetics, University of Copenhagen, The Panum Institute, Blegdamsvej 3c, DK-2200 N Copenhagen, Denmark.
Bioconjug Chem. 2003 Sep-Oct;14(5):941-54. doi: 10.1021/bc034022x.
A series of N-(2-aminoethyl)-alpha-amino acid thymine peptide nucleic acid (PNA) monomers bearing glycosylated side chains in the alpha-amino acid position have been synthesized. These include PNA monomers where glycine has been replaced by serine and threonine (O-glycosylated), derivatives of lysine and nor-alanine (C-glycosylated), and amide derivatives of aspartic acid (N-glycosylated). The Boc and Fmoc derivatives of these monomers were used for incorporation in PNA oligomers. Twelve PNA decamers containing the glycosylated units in one, two, or three positions were prepared, and the thermal stability (T(m)) of their complexes with a complementary RNA was determined. Incorporation of the glycosyl monomers reduced the duplex stability by 0-6 degrees C per substitution. A cysteine was attached to the amino terminus of eight of the PNA decamers (Cys-CTCATACTCT-NH(2)) for easy conjugation to a [(18)F]radiolabeled N-(4-fluorobenzyl)-2-bromoacetamide. The in vivo biodistribution of these PNA oligomers was determined in rat 2 h after intravenous administration. Most of the radioactivity was recovered in the kidneys and in the urine. However, N-acetylgalactosamine (and to a lesser extent galactose and mannose)-modified PNAs were effectively targeting the liver (40-fold over unmodified PNA). Thus, the pharmacodistribution in rats of PNA oligomers can be profoundly changed by glycosylation. These results could be of great significance for PNA drug development, as they should allow modulation and fine-tuning of the pharmacokinetic profile of a drug lead.
一系列在α-氨基酸位置带有糖基化侧链的N-(2-氨基乙基)-α-氨基酸胸腺嘧啶肽核酸(PNA)单体已被合成。这些单体包括甘氨酸被丝氨酸和苏氨酸取代的PNA单体(O-糖基化)、赖氨酸和去甲丙氨酸的衍生物(C-糖基化)以及天冬氨酸的酰胺衍生物(N-糖基化)。这些单体的Boc和Fmoc衍生物被用于掺入PNA寡聚物中。制备了12个在一个、两个或三个位置含有糖基化单元的PNA十聚体,并测定了它们与互补RNA形成的复合物的热稳定性(Tm)。每个糖基化单体的掺入使双链体稳定性降低0-6℃。在8个PNA十聚体的氨基末端连接了一个半胱氨酸(Cys-CTCATACTCT-NH₂),以便于与[(¹⁸)F]放射性标记的N-(4-氟苄基)-2-溴乙酰胺偶联。在静脉给药2小时后,测定了这些PNA寡聚物在大鼠体内的生物分布。大部分放射性活度在肾脏和尿液中被回收。然而,N-乙酰半乳糖胺(以及程度较轻的半乳糖和甘露糖)修饰的PNA能够有效地靶向肝脏(比未修饰的PNA高40倍)。因此,糖基化可深刻改变PNA寡聚物在大鼠体内的药物分布。这些结果对PNA药物开发可能具有重要意义,因为它们应该能够调节和微调先导药物的药代动力学特征。